United States Cancer Immunotherapy Market Report by Products, Application, End User, States and Company Analysis, 2026-2034

United States Cancer Immunotherapy Market: Future Outlook, Growth Trends & Forecast (2026–2034)

United States Cancer Immunotherapy Market is expected to reach US$ 137.4 Billion by 2034 from US$ 61.00 Billion in 2025, with a CAGR of 9.44% from 2026 to 2034. The U.S. cancer immunotherapy market is expanding through advances in immune checkpoint inhibitors, CAR-T therapies, bispecific antibodies, personalized cancer vaccines, and combination treatments. Growing oncology research, biomarker-guided treatment, improved clinical capabilities, and broader therapeutic applications are supporting market development.

United States Cancer Immunotherapy Industry Landscape

Cancer immunotherapy is a treatment approach that strengthens, redirects, or modifies the immune system to identify and attack cancer cells. Unlike conventional therapies that directly target rapidly dividing cells, immunotherapies work by enhancing immune recognition or introducing immune-based mechanisms against tumors. Major approaches include immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, cytokine therapies, bispecific antibodies, and chimeric antigen receptor T-cell therapies. Treatment may be used alone or combined with chemotherapy, radiation, targeted therapy, or surgery depending on the cancer type and patient characteristics. Advances in biomarkers, molecular diagnostics, cellular engineering, and personalized medicine are expanding the potential applications of immunotherapy across oncology.

The U.S. cancer immunotherapy market is being supported by continuous innovation in oncology treatment and the expanding use of immune-based therapies across different cancer types. Pharmaceutical and biotechnology companies are developing therapies designed to activate immune responses, overcome tumor resistance, and improve treatment specificity. Increasing use of biomarker testing is also helping physicians identify patients who may benefit from particular immunotherapy approaches. Meanwhile, advances in cell engineering are improving the development and delivery of CAR-T and other cellular therapies. Combination approaches involving immunotherapy with chemotherapy, targeted drugs, or other immune agents are creating additional treatment possibilities. Strong research capabilities, specialized cancer centers, and a mature clinical development ecosystem further support market expansion.

Recent Breakthroughs Shaping the United States Cancer Immunotherapy Industry

• June 2025: Bristol Myers Squibb and BioNTech announced a global strategic collaboration valued at up to US$11.1 billion to jointly develop BNT327, a bispecific antibody designed to target PD-L1 and VEGF-A. The partnership aims to advance the therapy across multiple solid-tumor indications.
• March 2024: Gilead Sciences announced plans to significantly expand its CAR-T manufacturing capacity by 2026, targeting a fourfold increase to support growing demand for cell-based cancer therapies and strengthen its ability to deliver these treatments at scale.

Major Growth Drivers Shaping the Future of United States Cancer Immunotherapy Sector

1. Breakthroughs in Cell and Gene-Based Immunotherapies

Advances in cellular immunotherapy are creating significant opportunities within the U.S. cancer treatment landscape. CAR-T therapy has demonstrated the ability to genetically modify a patient's own T cells so they can recognize and attack cancer cells. Research is now extending beyond established blood-cancer applications toward additional malignancies and increasingly sophisticated cell-engineering approaches. Improvements in manufacturing, treatment protocols, patient selection, and clinical infrastructure are helping expand access to these complex therapies. The regulatory environment is also evolving as experience with cellular therapies grows.

In June 2025, the FDA eliminated REMS requirements for currently approved BCMA- and CD19-directed autologous CAR-T immunotherapies, reducing an administrative burden associated with their use while maintaining existing safety requirements. Continued innovation in engineered immune cells, manufacturing platforms, and treatment combinations is expected to strengthen the role of cellular immunotherapy within the U.S. oncology market.

2. Expanding Role of Combination and Biomarker-Guided Immunotherapy

Combination treatment is becoming a central strategy for improving cancer immunotherapy outcomes. Researchers are combining immune checkpoint inhibitors with chemotherapy, targeted therapies, antibody-based treatments, radiation, and other immune-modulating agents to address different mechanisms of tumor growth and immune resistance. At the same time, biomarker testing is helping physicians identify tumors with characteristics that may make them more responsive to specific immune-based treatments. This supports a more personalized approach to cancer treatment and can improve treatment selection. Recent U.S. regulatory activity demonstrates the expanding applications of immunotherapy.

In April 2025, the FDA approved nivolumab with ipilimumab for previously untreated unresectable or metastatic hepatocellular carcinoma and also approved the combination for certain MSI-H or dMMR colorectal cancers. Such approvals broaden the addressable patient population and encourage pharmaceutical companies to explore additional combination regimens and biomarker-defined indications.

3. Convenient Formulations and Broader Immunotherapy Access

Immunotherapy market development is increasingly influenced by efforts to make established treatments more convenient for patients and healthcare providers. Pharmaceutical companies are developing alternative formulations and administration methods that can shorten treatment times, simplify delivery, and potentially reduce pressure on oncology infusion centers. These innovations can improve the patient experience while supporting healthcare systems managing growing demand for cancer treatment. The trend is particularly relevant for widely used checkpoint inhibitors, where reformulation can create new administration options without requiring an entirely new therapeutic mechanism.

In September 2025, the FDA approved Keytruda Qlex, a subcutaneous formulation of pembrolizumab and berahyaluronidase alfa-pmph, for adult and pediatric solid-tumor indications covered by intravenous pembrolizumab. The development demonstrates how formulation innovation can complement therapeutic advances and potentially broaden the practical use of immunotherapy in hospitals, outpatient centers, and other oncology settings.

Critical Challenges Facing the United States Cancer Immunotherapy Industry

1. High Treatment Complexity and Healthcare Infrastructure Requirements

Cancer immunotherapies can require highly specialized clinical expertise, sophisticated diagnostics, intensive monitoring, and dedicated treatment infrastructure. Cellular therapies such as CAR-T can involve complex patient selection, cell collection, manufacturing, administration, and post-treatment monitoring. Certain immunotherapies can also cause serious immune-related adverse events that require rapid identification and specialized management. These requirements can make treatment more difficult to deliver outside major cancer centers. Smaller hospitals and community oncology practices may face challenges related to trained personnel, laboratory capabilities, treatment coordination, and emergency support. Manufacturing and logistics can also complicate personalized cellular therapies because treatment materials may need to move through tightly controlled processes. As the number of immunotherapy options increases, healthcare providers must continually invest in staff training, diagnostic capabilities, monitoring systems, and specialized infrastructure. Improving treatment accessibility while maintaining safety and quality remains an important challenge for market expansion.

2. Treatment Costs, Reimbursement, and Patient Access

The financial burden associated with advanced cancer immunotherapies can create barriers for patients, healthcare providers, and payers. Complex biologic medicines and personalized cellular therapies can involve substantial development, manufacturing, administration, monitoring, and supportive-care requirements. Reimbursement policies may vary according to therapy, indication, insurance coverage, treatment setting, and patient eligibility. Hospitals may also need to manage significant operational costs when delivering sophisticated immunotherapy programs. Access can become particularly challenging when patients require specialized cancer centers that are distant from their homes, creating additional travel and logistical burdens. At the same time, treatment decisions increasingly depend on biomarker testing, which adds another component to the overall care pathway. Expanding the use of immunotherapy therefore requires not only scientific progress but also sustainable reimbursement models, broader provider capabilities, patient assistance mechanisms, and efficient care delivery systems that can make advanced treatments more accessible.

California — The Golden State of Immuno-Oncology Innovation

California is one of the most important markets for cancer immunotherapy in the United States because of its concentration of biotechnology companies, academic institutions, pharmaceutical organizations, research hospitals, and specialized cancer centers. The state supports extensive clinical research into immune checkpoint inhibitors, CAR-T therapies, cancer vaccines, bispecific antibodies, and personalized oncology. The San Francisco Bay Area and San Diego are particularly important biotechnology clusters, while Los Angeles and other metropolitan areas provide large patient populations and sophisticated healthcare infrastructure. California's research ecosystem also supports collaboration among universities, hospitals, biotechnology firms, and pharmaceutical companies, accelerating translation from laboratory discoveries into clinical programs. The state's diverse population creates demand for broad oncology services and advanced diagnostic testing. Specialized treatment centers are increasingly important as cellular and personalized therapies require sophisticated administration and monitoring. California is therefore positioned as both a major treatment market and an innovation hub for next-generation cancer immunotherapies.

Texas — A Powerhouse for Advanced Cancer Treatment

Texas represents a major cancer immunotherapy market supported by extensive healthcare infrastructure, specialized oncology institutions, biotechnology activity, and a large patient population. Houston is particularly prominent because of its concentration of comprehensive cancer treatment and research capabilities, while Dallas, Austin, San Antonio, and other cities contribute to the state's broader oncology ecosystem. Large medical institutions support clinical trials, advanced diagnostics, immunotherapy administration, cellular therapy, and multidisciplinary cancer care. Texas also provides a substantial environment for pharmaceutical and biotechnology companies seeking clinical research partnerships and access to specialized healthcare professionals. The state's expanding technology ecosystem can support the adoption of data-driven oncology, digital diagnostics, and AI-assisted treatment development. As immunotherapy increasingly involves complex biomarker testing and personalized treatment planning, Texas's specialized medical infrastructure creates favorable conditions for adoption. Continued research activity and investment in cancer centers are expected to reinforce the state's position within the U.S. immunotherapy landscape.

New York — Where Precision Oncology Meets Immunotherapy

New York is a significant cancer immunotherapy market due to its extensive network of hospitals, academic medical centers, research institutions, pharmaceutical organizations, and biotechnology companies. New York City provides particularly strong demand for advanced oncology treatments because of its concentration of specialized cancer centers and large, diverse patient population. The state supports research across immune checkpoint inhibitors, cellular therapies, targeted immunotherapy combinations, and personalized cancer treatment. Academic institutions and healthcare organizations contribute to clinical trials and translational research, creating pathways for emerging immunotherapies to reach patients. The state's strong pharmaceutical and biotechnology presence further supports collaboration between drug developers and clinical researchers. Advanced diagnostic services are also important because biomarker testing increasingly guides immunotherapy selection. New York's combination of clinical expertise, research capabilities, specialized treatment facilities, and pharmaceutical activity positions it as an important market for established immunotherapies as well as emerging cellular and precision oncology technologies.

Florida — A Growing Destination for Advanced Oncology Care

Florida is an increasingly important market for cancer immunotherapy, supported by its large and diverse population, expanding healthcare infrastructure, specialized cancer centers, and growing demand for advanced treatment services. Major metropolitan areas such as Miami, Tampa, Orlando, and Jacksonville provide extensive oncology services and increasingly sophisticated treatment capabilities. The state's healthcare ecosystem supports immune checkpoint therapies, targeted combinations, cellular treatments, and advanced diagnostic services. Florida's substantial older population also contributes to demand for comprehensive cancer care and specialized oncology management. Healthcare providers are increasingly developing multidisciplinary programs that combine medical oncology, radiation oncology, surgery, diagnostics, and immunotherapy. The expansion of specialized cancer centers can improve access to complex treatments that require experienced clinical teams and monitoring capabilities. As providers continue investing in advanced oncology infrastructure, Florida is positioned to capture growing demand for immunotherapy while also supporting clinical research and adoption of emerging cancer treatment technologies.

United States Monoclonal Antibodies Market

The U.S. monoclonal antibodies market is a major component of modern oncology and immunotherapy because these biologic medicines can selectively bind to specific targets involved in cancer development or immune regulation. Monoclonal antibodies are used as standalone treatments and in combination with chemotherapy, targeted therapies, or other immunotherapies. Their applications include immune checkpoint inhibition, tumor-targeted treatment, immune-cell recruitment, and delivery of therapeutic agents. Advances in antibody engineering are producing more sophisticated molecules, including bispecific antibodies and antibody-drug conjugates, which can improve target specificity or connect immune cells with cancer cells. The market is supported by extensive pharmaceutical research, established biologics manufacturing capabilities, specialized oncology centers, and biomarker-driven treatment strategies. Continued development of new targets and combination approaches is expanding potential applications. Competition is increasingly focused on improving efficacy, safety, dosing convenience, and patient selection while developing differentiated antibody-based therapies for diverse cancers.

United States Lung Cancer Immunotherapy Market

The U.S. lung cancer immunotherapy market is driven by the expanding role of immune-based treatments in non-small cell and small cell lung cancer. Immune checkpoint inhibitors are increasingly incorporated into treatment strategies, either alone or alongside chemotherapy, targeted therapies, or other agents depending on tumor characteristics and patient eligibility. Biomarker testing is important for treatment selection because factors such as PD-L1 expression and specific molecular alterations can influence therapeutic decisions. The market is also evolving through the development of newer immune mechanisms, including bispecific T-cell engagers. In November 2025, the FDA granted traditional approval to tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer whose disease progressed following platinum-based chemotherapy. This development illustrates the expansion of immune-based treatment options beyond conventional checkpoint inhibition and highlights continued innovation within lung cancer immunotherapy.

United States Hospital Cancer Immunotherapy Market

The U.S. hospital cancer immunotherapy market encompasses immunotherapy administration, monitoring, diagnostic support, cellular therapy, and multidisciplinary oncology services delivered through hospitals and specialized cancer centers. Hospitals remain critical because many advanced immunotherapies require specialized facilities, trained oncology professionals, laboratory capabilities, emergency support, and coordinated patient monitoring. The increasing use of CAR-T therapies, bispecific antibodies, immune checkpoint inhibitors, and personalized treatment strategies is encouraging hospitals to strengthen oncology infrastructure. Diagnostic testing is also becoming increasingly integrated into treatment pathways as biomarkers influence therapy selection. Large academic hospitals and comprehensive cancer centers often serve as clinical research sites, helping introduce emerging immunotherapies into routine practice. Meanwhile, outpatient oncology facilities are expanding their role in administering selected treatments when clinically appropriate. Hospital providers are therefore investing in infusion capacity, cellular therapy programs, pharmacy services, patient monitoring, and specialized staff to support the growing complexity of immunotherapy delivery across the United States.

Market Segmentation

Products

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines

Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head & Neck Cancer
• Others

End Users

• Hospital
• Cancer Research Center
• Clinics

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. Amgen Inc.
2. AstraZeneca
3. Bayer AG
4. Bristol-Myers Squibb Company
5. Pfizer Inc.
6. Novarts AG
7. Johnson & Johnson
8. Eli Lily Company
9. Seattle Genetics Inc.

Report Details: